/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

Y

Yasuhito Fujisaka

Osaka Medical and Pharmaceutical University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

104

Papers

5.1K

Citations

19

h-index

32

i10-index

Yasuhito Fujisaka is an academic researcher from Osaka Medical and Pharmaceutical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Cancer Treatment and Pharmacology. The author has an h-index of 19, co-authored 89 publications.

ORCID: 0000-0002-9175-3627

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Cancer Treatment and Pharmacology Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research

Papers by this author

works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

2011 · Science Translational Medicine · 661 citations

https://doi.org/10.1126/scitranslmed.3002442

Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

2011 · Biochemical and Biophysical Research Communications · 53 citations

https://doi.org/10.1016/j.bbrc.2011.03.002

Koichi Azuma Junji Tsurutani Kazuko Sakai Hiroyasu Kaneda

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

2014 · Investigational New Drugs · 43 citations

https://doi.org/10.1007/s10637-014-0196-0

Yasuhito Fujisaka Takayasu Kurata Kaoru Tanaka Toshihiro Kudo

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)

2024 · JTO Clinical and Research Reports · 13 citations

https://doi.org/10.1016/j.jtocrr.2024.100720

Kageaki Watanabe Yukio Hosomi Katsuhiko Naoki Yoshiro Nakahara

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

2014 · Investigational New Drugs · 12 citations

https://doi.org/10.1007/s10637-014-0112-7

Takayasu Kurata Junji Tsurutani Yasuhito Fujisaka Wataru Okamoto

Research topics

topics

Lung Cancer Treatments and Mutations

Lung Cancer Diagnosis and Treatment

Cancer Treatment and Pharmacology

Colorectal Cancer Treatments and Studies

HER2/EGFR in Cancer Research

Chat about Author

Papers

Chat

Click to start Chat